IVMED

IVMED is a clinical-stage biopharmaceutical company focused on developing non-surgical, pharmacologic treatments for corneal diseases and refractive errors. The company's lead candidate, IVMED-80, is a proprietary topical copper-sulfate formulation designed to induce endogenous corneal collagen cross-linking to treat keratoconus. By increasing the activity of lysyl oxidase, IVMED's approach aims to strengthen the cornea without the need for surgical intervention or UV light exposure. This pharmacologic cross-linking method represents a potential paradigm shift in treating progressive corneal thinning. The company is also exploring the application of its technology for the treatment of myopia, targeting the sclera to prevent eye elongation. IVMED has established a strategic partnership with Glaukos Corporation to advance its clinical programs.